NCT07815236Not yet recruitingPhase 2/3
Diabetes Prevention Through Genetics, Familial History and Behavior Change
Legacy-DPP: Diabetes Prevention Through Genetics, Familial History and Behavior Change A Family-Enhanced, Genetically-Informed Diabetes Prevention Program
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes. It will also learn about the effects of this approach on family members' health. The main questions it aims to answer are: * Does adding family health history collection and family participation to the DPP improve session attendance compared to standard DPP? * Does this family-centered approach lead to greater weight loss and HbA1c (blood sugar) reduction compared to standard DPP? * Do health improvements extend to participants' family members, and what factors explain differences in family-level outcomes? Researchers will compare an adapted DPP with a family component to the standard DPP (individual-focused) to see if involving family members improves diabetes prevention outcomes. Participants will: * Be assigned to one of two groups: adapted DPP with family sessions, or standard DPP * If assigned to the adapted DPP, complete a family health history using the Center for Disease Control and Prevention's (CDC) My Family Health Portrait tool and attend 6 additional sessions with family members focused on personalized risk communication * Attend regular checkups to measure weight and HbA1c at 6 and 12 months * Have session attendance tracked throughout the program * Family members of participants may also be asked to complete health assessments to measure any changes in their own health behaviors
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 6 Sept 2026
- Start date
- Jan 2027
- Primary completion date
- Jan 2031
- Lead sponsor
- Morehouse School of Medicine
- Diseases
- Type 2 diabetes
- NCT number
- NCT07815236
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 400
- From Jan 2027 to the primary completion date, Jan 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior diagnosis of Type 1 or Type 2 Diabetes.
Lab values
- HbA1c ≥6.5% at screening (Aim 1/2 curriculum eligibility)
- Current glucose-lowering medication use
Age
- Minors \<18 years
Other
- Pregnancy
- Physical-activity contraindications
- Individuals unable to speak or understand English
Who the study is looking for
- Age ≥18 years.
- Fasting HbA1c 5.7-6.4% confirmed by CLIA-waived point-of-care testing.
- Body Mass Index ≥25 kg/m².
- Able to provide informed consent.
- Has an adult household/family or framily (fictive kin) member willing to enroll as a paired participant.
- Willing to attend in-person sessions
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.